Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours
Abstract Background Neuroblastoma (NB) is a paediatric tumour of the sympathetic nervous system. Half of all cases are defined high-risk with an overall survival less than 40% at 5 years from diagnosis. The lack of in vitro models able to recapitulate the intrinsic heterogeneity of primary NB tumour...
Main Authors: | P. Fusco, B. Parisatto, E. Rampazzo, L. Persano, C. Frasson, A. Di Meglio, A. Leslz, L. Santoro, B. Cafferata, A. Zin, E. Cimetta, G. Basso, M. R. Esposito, G. P. Tonini |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-10-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-6149-4 |
Similar Items
-
Progress of oncolytic virotherapy for neuroblastoma
by: Xiao-Tong Chen, et al.
Published: (2022-11-01) -
Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma
by: Albatool AlKhazal, et al.
Published: (2025-03-01) -
Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions
by: Min Zheng, et al.
Published: (2024-03-01) -
Living biobank-based cancer organoids: prospects and challenges in cancer research
by: Haixin Li, et al.
Published: (2022-07-01) -
From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models
by: Mario Capasso, et al.
Published: (2024-02-01)